SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. VIR today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus (HBV) and hepatitis D virus (HDV) have been accepted for presentation at the annual meeting of the European Association…Read More
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL Congress 2023 Vir Biotechnology NASDAQVIR
